Herbimycin C (CAS 91700-92-4)

Herbimycin C, a benzoquinoid ansamycin antibiotic derived from Streptomyces hygroscopicus, has garnered significant attention in scientific research due to its potent inhibitory activity against protein tyrosine kinases (PTKs). Mechanistically, Herbimycin C functions as a competitive inhibitor of ATP binding to the catalytic domain of PTKs, thereby impeding phosphorylation of tyrosine residues and disrupting downstream signaling cascades involved in cell proliferation, differentiation, and survival. This unique mechanism of action has led to its widespread use as a valuable tool in elucidating the role of protein tyrosine kinases in various cellular processes and disease states. In research, Herbimycin C has been employed to investigate the molecular mechanisms underlying cancer progression, as aberrant activation of protein tyrosine kinases is frequently implicated in oncogenesis. Additionally, Herbimycin C has been utilized to explore the signaling pathways involved in cellular responses to stress, immunity, and development. Furthermore, Herbimycin C′s ability to inhibit protein tyrosine kinases has sparked interest in its potential application as an agent for diseases characterized by dysregulated kinase activity.